
Follow the funds: Australia’s daily VC deals
Forbes Australia presents the latest in the world of Venture Capital every day. For the latest news on funds, innovation and the businesses attracting the money, visit us here.
Forbes Australia presents the latest in the world of Venture Capital every day. For the latest news on funds, innovation and the businesses attracting the money, visit us here.
Bart Stephens, cofounder and managing partner of crypto fund Blockchain Capital who was an early and prominent evangelist for cryptocurrencies, has filed a lawsuit against an anonymous hacker who stole $6.3 million of bitcoin, ether and other cryptocurrencies from his digital wallets.
Australian adults lost more than US$80,000 across 2022 compared to 2021, due in large part to stock market losses, the 2023 UBS Global Wealth Report has revealed.
Apple, Delta Airlines, Facebook and Juul are among the companies with pending class action lawsuits.
Investment firm BlackRock has predicted the US economy is set for “full-employment stagnation”, which is different to the job-less recessions and recoveries we’ve seen in the past, it claims.
Forbes Asia’s Best Under a Billion list, which highlights 200 small and midsized publicly traded companies in the Asia-Pacific region with annual sales above US$10 million and below US$1 billion, has recognised 18 Australian businesses.
A day after office co-working start-up WeWork revealed there was “substantial doubt” about its ability to continue, its share price has dropped again. But how did it get here?
While-label partner Paxos, smarting from loss of Binance token, said to be in talks with slew of financial firms.
PayPal became the first online payment giant to enter the cryptocurrency arena on Monday by rolling out a stablecoin pegged to the U.S. dollar, sending its shares up nearly 3% despite a turbulent crypto market and as PayPal’s stock dipped to a six-year low in the wake of decreased consumer spending last year.
Moderna and BioNTech shares both cratered to their lowest price in years Monday as the companies behind the most widely-circulated mRNA Covid-19 vaccines grapple with investor disappointment with crashing revenues.